Chemotherapy and the heart;La quimioterapia y el corazón

Revista Espanola de Cardiologia

Volumn 64, Issue 5, 2011, Pages 409-415

  Plana, Juan C ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracyclins; Cardiotoxicity; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM EXAMINATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; HEART EJECTION FRACTION; HUMAN; IMAGE QUALITY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; SYSTOLIC DYSFUNCTION; THREE DIMENSIONAL ECHOCARDIOGRAPHY;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; NEOPLASMS;

EID: 79955668570     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2010.12.013     Document Type: Article

References (51)

1. National Cancer Institute. SEER Cancer Statistics Review 1975-2007. Disponible en: http://seer.cancer.gov/csr/1975-2007/index.html
2. Cancer survivorship -United States, 1971-2001. MMWR Morb Mortal Wkly Rep. 2004;53:526-9.
3. Mann DL, Krone RJ. Cardiac disease in cancer patients: An overview. Prog Cardiovasc Dis. 2010;53:80-7.
4. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage t1a,bn0m0 breast carcinoma. J Clin Oncol. 2007;25:4952-60. (Pubitemid 350220427)
5. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435-41. (Pubitemid 47494586)
6. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430-40. (Pubitemid 34685700)
7. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466-8. (Pubitemid 14012819)
8. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIβ-mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Science. 2007;67:8839-46. (Pubitemid 47437460)
9. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-7. (Pubitemid 10218041)
10. Neilan TG, Jassal DS, Pérez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, et al. Tissue doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J. 2006;27:1868-75. (Pubitemid 44297395)
11. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-84. (Pubitemid 30207690)
12. Chien KR. Herceptin and the heart -a molecular modifier of cardiac failure. N Engl J Med. 2006;354:789-90. (Pubitemid 43290916)
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
14. Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother. 2008;42:99-104.
15. Jurcut R, Wildiers H, Ganame J, D'Hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer. 2008;16:437-45.
16. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain; comparison with ejection fraction and wall motion scoring index. Circ Cardiovasc imaging. 2009;2:356-64.
17. Chuang ML, Hibberd MG, Salton CJ, Beaudin RA, Riley MF, Parker RA, et al. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: Assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. J Am Coll Cardiol. 2000;35:477-84. (Pubitemid 30125541)
18. Skrypniuk JV, Bailey D, Cosgriff PS, Fleming JS, Houston AS, Jarritt PH, et al. UK audit of left ventricular ejection fraction estimation from equilibrium ecg gated blood pool images. Nucl Med Commun. 2005;26:205-15. (Pubitemid 40411044)
19. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the childrens cancer study group. Pediatrics. 1992;89:942-9.
20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-235.
21. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-18.
22. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33:2-14. (Pubitemid 43214484)
23. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-32. (Pubitemid 27167363)
24. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-54. (Pubitemid 32202552)
25. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposomeen-capsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36. (Pubitemid 34049039)
26. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by her2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-95. (Pubitemid 32441364)
27. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-700. (Pubitemid 34712910)
28. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709. (Pubitemid 34567375)
29. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300:278-83. (Pubitemid 9115687)
30. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21:1179-201.
31. Jacobs LD, Salgo IS, Goonewardena S, Weinert L, Coon P, Bardo D, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27:460-8. (Pubitemid 43209172)
32. Mor-Avi V, Sugeng L, Lang RM. Real-time 3-dimensional echocardiography: An integral component of the routine echocardiographic examination in adult patients? Circulation. 2009;119:314-29.
33. Corsi C, Coon P, Goonewardena S, Weinert L, Sugeng L, Polonsky TS, et al. Quantification of regional left ventricular wall motion from real-time 3-dimensional echocardiography in patients with poor acoustic windows: Effects of contrast enhancement tested against cardiac magnetic resonance. J Am Soc Echocardiogr. 2006;19:886-93. (Pubitemid 43974917)
34. Moller JE, Sondergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: A serial color m-mode doppler echocardiographic study. J Am Coll Cardiol. 2000;36:1841-6.
35. Moller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. Circulation. 2006;114:438-44. (Pubitemid 44264826)
36. Moller JE, Whalley GA, Dini FL, Doughty RN, Gamble GD, Klein AL, et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: An individual patient meta-analysis: Meta-analysis research group in echocardiography acute myocardial infarction. Circulation. 2008;117:2591-8.
37. Nijland F, Kamp O, Karreman AJ, Van Eenige MJ, Visser CA. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: A serial Doppler echocardiographic study. J Am Coll Cardiol. 1997;30:1618-24. (Pubitemid 27521241)
38. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-31.
39. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure -abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-9.
40. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: Interest of doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118:92-8. (Pubitemid 19183582)
41. Pudil R, Horacek JM, Strasova A, Jebavy L, Vojacek J. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol. 2008;30:160-2. (Pubitemid 351951396)
42. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62-9.
43. Bountioukos M, Doorduijn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, et al. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr. 2003;4:300-5. (Pubitemid 37455879)
44. Cottin Y, L'Huillier I, Casasnovas O, Geoffroy C, Caillot D, Zeller M, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr. 2000;1:180-3.
45. Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatr Int. 2006;48:313-20.
46. Jarfelt M, Kujacic V, Holmgren D, Bjarnason R, Lannering B. Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49:835-40. (Pubitemid 47519523)
47. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol. 2009;54:618-24.
48. Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: Definition of normal range. JACC Cardiovasc Imaging. 2009;2:80-4.
49. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158:294-301.
50. Sawaya HSI, Plana JC, Januzzi JL, Ky B, Cohen V, Carver J, et al. Early detection and prediction of cardiotoxicity in chemotherapy treated patients; an echocardiographic and biomarker study. American Society of Echocardiography 2010 Scientific Sessions; June 13, 2010; San Diego, CA. Abstract P1-42. Disponible en: http://www.asecho.org/files/EAC2010.PDF
51. Jurcut R, Wildiers H, Ganame J, D'Hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J AmSoc Echocardiogr. 2008;21:1283-9.